Scarica l'app Stockscreener
18.25
2.98%
-0.56
Dopo l'orario di chiusura:
18.25
Precedente Chiudi:
$18.81
Aprire:
$18.59
Volume 24 ore:
1.25M
Relative Volume:
0.61
Capitalizzazione di mercato:
$2.60B
Reddito:
-
Utile/perdita netta:
$-45.61M
Rapporto P/E:
-56.41
EPS:
-0.3235
Flusso di cassa netto:
$-45.40M
1 W Prestazione:
+0.55%
1M Prestazione:
+8.83%
6M Prestazione:
+71.52%
1 anno Prestazione:
+145.96%
Intervallo 1D:
$18.15
$18.99
Intervallo di 1 settimana:
$17.63
$19.30
Portata 52W:
$6.93
$20.22
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
18.25 | 2.68B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
TREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - Bitget
Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - marketbeat.com
Raymond James raises Trevi Therapeutics price target on pipeline progress By Investing.com - Investing.com Australia
TRVI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights - GuruFocus
Earnings call transcript: Trevi Therapeutics posts small Q2 2026 EPS miss - Investing.com UK
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... - Yahoo Finance
Trevi Therapeutics (TRVI) Advances Clinical Trials Amid High Val - GuruFocus
Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Trevi Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Trevi Q2 2026 Earnings: Higher Trial Spending Widens the Net Loss - TradingKey
Trevi Therapeutics, Inc. 2Q 2026: Net loss $17.8M, EPS $(0.11) — 10-Q Summary - TradingView
Trevi Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Trevi Therapeutics (NASDAQ: TRVI) funds late-stage cough trials with $318.9M - Stock Titan
Trevi Therapeutics reports Q2 2026 net loss of $17.8M; $318.9M cash and marketable securities - TradingView
Trevi Therapeutics faces earnings test as Haduvio trials advance By Investing.com - Investing.com Nigeria
Trevi Therapeutics faces earnings test as Haduvio trials advance - Investing.com
FMR LLC discloses 8.8% Trevi Therapeutics (TRVI) ownership in amended 13G - Stock Titan
$Trevi Therapeutics (TRVI.US)$ squeeze baby squeeze - Moomoo
Trevi Therapeutics (TRVI) Advances 4.75% as Biotech Momentum StrengthensOn Balance Volume - dars.gov.et
TRVI Q1 2026 Earnings: Wider Than Expected Loss of -$0.09 Per Share; Shares Dip 0.82%Earnings Preview - Vinanet
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics sets Aug. 6 update on chronic-cough therapy - Stock Titan
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):